Starpharma (ASX:SPL)
ASX announcement history & article coverage
Transparent by design.
Announcments by Starpharma (ASX:SPL) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ceasing to be a substantial holder
2026 Appendix 4G and Corporate Governance Statement
2026 Annual Report
Starpharma advances DEP® platform, secures major partnerships, plans clinical trial for lead radiopharmaceutical, reports FY26 loss of $7.5M
FY26 Key Financial Results and Annual Report
Starpharma FY26 revenue surges 145%, loss narrows, $30M raised to extend funding runway
Preliminary Final Report
Company reports 145% revenue increase and reduced loss for FY 2026 driven by Genentech collaboration
Becoming a substantial holder
Ceasing to be a substantial holder
Change in substantial holding
Change in substantial holding
Change of Director Interest Notice - R Basser
Change of Director Interest Notice - R Thomas
Change of Director Interest Notice - L Cheng
Change of Director Interest Notice - J Davies
Change of Director Interest Notice - C Maley
Becoming a substantial holder
Application for quotation of securities - SPL
Successful Completion of $32 million Entitlement Offer
Starpharma completes $32 million entitlement offer to fund oncology pipeline advancement
Letter to Ineligible Shareholders
Letter to Eligible Shareholders
Ceasing to be a substantial holder
Entitlement Offer Booklet
Starpharma launches fully underwritten AUD 32 million entitlement offer at AUD 0.57 per share
Cleansing Notice
Proposed issue of securities - SPL
Entitlement Offer Investor Presentation
Starpharma launches fully underwritten A$32 million entitlement offer to fund DEP® HER2-Lutetium clinical trials and oncology pipeline expansion
Fully Underwritten Entitlement Offer to Raise $32 Million
Starpharma launches fully underwritten $32 million entitlement offer to fund oncology pipeline
Quarterly Activities Report and Appendix 4C
Starpharma advances DEP® HER2-Lu to Phase 1 trial, files new patent, and secures $0.5M milestone payment
DEP HER2 Investor Webinar
DEP milestone triggers partner option fee
Starpharma milestone triggers AUD 0.5 million option fee from Radiopharm with potential AUD 91 million licensing deal
Positive DEP HER2-Lu preclinical data support Phase 1 entry
Starpharma's DEP® HER2-Lu shows promising preclinical data, advancing to Phase 1 trial in H2 2026
DEP radiopharmaceutical data supports patent application
Starpharma files patent for DEP® radiopharmaceutical platform after positive preclinical data
Becoming a substantial holder
Becoming a substantial holder